

## Bulletin for Community Pharmacists and Pharmacy Technicians:

### Updated [Opioids Aware](https://www.fpm.ac.uk/opioids-aware) Dose Guidance

**Source:** Faculty of Pain Medicine, Royal College of Anaesthetists

**Full guidance:** <https://www.fpm.ac.uk/opioids-aware>

**Scope:** Applies to opioid use **excluding sickle cell disease, palliative care, and end-of-life care.**

#### **Key Update: Revised Oral Morphine Equivalent dose (OME) thresholds for opioid use excluding sickle cell disease, palliative care, and end-of-life care**

- The recommended **oral morphine equivalent (OME)** threshold for opioid use **excluding sickle cell disease, palliative care, and end-of-life care** has been **reduced from 120mg to 90mg/day**, with an **ideal target of 50mg/day**. These are more clearly designated as guidance and exceptions may be clinically appropriate
- The guidance now emphasises that **doses above 90mg OME/day rarely provide additional benefit** for chronic non-cancer pain **excluding sickle cell disease, palliative care, and end-of-life care**, and significantly increases the risk of harm.
- Pharmacists are encouraged to **flag patients not in the excluded groups who are approaching or exceeding 90–120 mg OME/day** for clinical review and to highlight or discuss with the prescriber before further dose escalation, unless clearly justified.

#### **Other Important Changes**

- **Stronger expectation of regular review:** Opioid therapy should be reassessed routinely for functional benefit, adverse effects, and signs of dependence.
- **Clearer direction to avoid escalation:** Dose increases should not be routine; pharmacists should be alert to rapid titration, early supply requests, or lack of functional improvement.
- **Reinforced shared decision-making:** Patients should be supported to understand realistic expectations, risks of long-term opioid use, and non-pharmacological alternatives.

- **Safeguarding:** New information on safeguarding considerations when prescribing strong opioids, especially in vulnerable populations.
- **Terminology:** Clarity on the use of terminologies when describing opioids
- **Updated patient information section** Updates to content, language and format and updated patient information leaflets.

## Opioids Aware is a continually updated document that evolves as new evidence emerges

- A useful patient centred resource in this arena is the [Live Well with Pain](#) website which hosts useful resources and patient information. Of specific note is the patient leaflet [Living with persistent pain- where do medicines fit in?](#)
- The [Flippin' Pain](#) website also contains many helpful resources.
- A review of pain medication may include the following points/considerations:
  - Opportunity to talk about how you are getting on with your medication
  - Any concerns taking your medicine
  - What to do if you forget to take your regular medicines
  - Is the medicine and dose still right for your condition, taking into account any co morbidities?
  - If medication is not effective, or no longer required, then discuss stopping.
  - Opportunity to talk about side effects and ask questions
  - Shared decision making and plan what medication to take if for flares- consider lower maintenance dose



### Implications for Community Pharmacy

- Integrate the revised OME thresholds into clinical checks for all chronic opioid prescriptions **excluding sickle cell disease, palliative care, and end-of-life care.**
- Prompt prescribers when doses approach high-risk levels or when therapy appears ineffective.
- Provide consistent, evidence-based messaging to patients about safe opioid use.
- Document interventions as part of routine clinical governance.
- A recent [Coroner's report](#) and [article](#) has highlighted the importance of regular review and dose reduction in people using opioids for non-cancer pain.

## Counselling on Paediatric and Liquid Medicines

We have recently received reports where parents and carers misunderstood the **volume of liquid medication** to administer, resulting in **incorrect doses being given**. Clear, practical counselling at the point of supply is therefore essential.

Prescribers will be reminded to reinforce dosing instructions when issuing small-volume liquid medicines. However, they will not have access to the medication pack or an oral syringe during the consultation, so **community pharmacy counselling remains essential**.

### Key actions for community pharmacies

- Provide **verbal counselling** for all paediatric and liquid medicines, especially where doses are small or unusual (e.g., <1 millilitre).
- **Demonstrate the exact volume** using an oral syringe or dosing device whenever possible.
- **Check** that parents/carers understand:
  - the prescribed dose
  - the correct measuring device
  - how to draw up and administer the volume
  - the dosing frequency and duration
- Supply an **appropriate oral syringe** and ensure it matches the dose volume.
- **Encourage** parents/carers to repeat back the instructions to confirm understanding ([TeachBack](#)).

Your support is vital in preventing medication errors and ensuring safe, effective treatment for children and young people. Thank you for continuing to provide high-quality counselling and patient-centred care.

---